Please assess the completion status of the following clinical trial:

Trial Title: Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age minimum: 18 years old~* Histological confirmation of prostatic adenocarcinoma~* PSA \> or = to 2 ng/ml~* PSA progression (serially rises on two occasions each at least one week apart) OR disease progression on imaging studies (CT scan or bone scan).~* Minimally symptomatic - no symptoms attributed to prostate cancer greater than Grade I based on NCI CTCAE Version 4.0 grading of toxicities~* Discontinuation of all antiandrogen, ketoconazole and investigational drugs for at least 4 weeks (6 weeks for bicalutamide) prior to study initiation~* Maintain castrate levels of testosterone (\<50ng/dL)~* Karnofsky Performance Status \> or = to 60%~* Life expectancy \> 3 months~* Adequate hematologic, renal, and liver function~Exclusion Criteria:~* Currently active second malignancy other than non-melanoma skin cancers.~* Clinically significant cardiovascular disease: EF \< 30%, NHYA Class III or greater congestive heart failure, myocardial infarction/unstable angina within 6 months prior to study enrollment, or significant ECG abnormalities such as QRS/QT prolongation (see Section 5.3).~* Progressive pulmonary disease, such as advanced COPD, pulmonary fibrosis, or supplemental O2 requirement.~* Known CNS disease, except for treated brain metastases.~* Poorly controlled diabetes mellitus (HbA1c \> 7 %) or fasting blood glucose level \>126 mg/dL in non-diabetic patients or \> 189 mg/dL in diabetic patients (can be enrolled after initiation or titration of anti-diabetic agent(s)).~* Poorly controlled hypercholesterolemia (fasting serum cholesterol \>300 mg/dL) or hypertriglyceridemia (\> 2.5 x ULN). Patients above either threshold can be included after initiation of appropriate lipid lowering medication.~* Current use of chronic steroids (equivalent of 20mg prednisone daily). Inhaled steroids are acceptable.~* Active gallbladder disease or hepatitis (AST or ALT \> 2.0, or bilirubin \> 1.5x ULN), liver cirrhosis, or severe liver impairment (Child-Pugh class C). It is highly recommended that patients positive for HBV-DNA or HBsAg are treated prophylactically with an antiviral for 1-2 weeks prior to receiving study drug.~* Serum creatinine \>1.5 upper limit of normal or on dialysis.~* Prior use of a somatostatin analog or mTOR inhibitor for the treatment of PC.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort A (pasireotide) (Type: ACTIVE_COMPARATOR): Patients receive pasireotide IM once every 4 weeks
- Cohort B (pasireotide and everolimus) (Type: EXPERIMENTAL): Patients receive pasireotide as in cohort A and everolimus PO QD

Based on this trial design, predict the completion outcome and termination type (if applicable).